Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZV Immunogenicity in IBD Patients on Biologics
NCT06224270Phase 4Withdrawn
- Sponsor
- University of Wisconsin–Madison
- Start
- Oct 2024
- Primary completion
- Sep 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by University of Wisconsin–Madison. Primary endpoint: Geometric Mean Concentrations of Anti-gE Antibodies. Planned start Oct 2024; status: withdrawn.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06224270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224270.